Kejing Ying

Dr. Kejing Ying


Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 January 2022 in Cancer Cell International
Verified
Journal Article
Open access
PDF file
YXYiming Xu
Yiming Xu
DLDandan Lv
Dandan Lv
CYChao Yan
Chao Yan
HSHua Su
Hua Su
XZXue Zhang
Xue Zhang
KYKejing Ying
Kejing Ying
Background: N6-methyladenosine (m6A) has emerged as a significant regulator of the progress of various cancers. However, its role in lung adenocarcinoma (LUAD) remains unclear. Here, we explored the biological function and underlying mechanism of methyltransferase-like 3 (METTL3), the main catalyst of m6A, in LUAD progression. Methods: The expression of m6A, METTL3, YTHDF1 and SLC7A11 were detected by immunochemistry or/and online datasets in LUAD patients. The effects of METTL3 on LUAD cell proliferation, apoptosis and ferroptosis were assessed through in vitro loss-and gain-of-function experiments. The in vivo effect on tumorigenesis of METTL3 was evaluated using the LUAD cell xenograft mouse model. MeRIP-seq, RNA immunoprecipitation and RNA stability assay were conducted to explore the molecular mechanism of METTL3 in LUAD. Results: The results showed that the m6A level, as well as the methylase METTL3 were both significantly elevated in LUAD patients and lung cancer cells. Functionally, we found that METTL3 could promote proliferation and inhibit ferroptosis in different LUAD cell models, while METTL3 knockdown suppressed LUAD growth in cell-derived xenografts. Mechanistically, solute carrier 7A11 (SLC7A11), the subunit of system Xc−, was identified as the direct target of METTL3 by mRNA-seq and MeRIP-seq. METTL3-mediated m6A modification could stabilize SLC7A11 mRNA and promote its translation, thus promoting LUAD cell proliferation and inhibiting cell ferroptosis, a novel form of programmed cell death. Additionally, we demonstrated that YTHDF1, a m6A reader, was recruited by METTL3 to enhance SLC7A11 m6A modification. Moreover, the expression of YTHDF1 and SLC7A11 were positively correlated with METTL3 and m6A in LUAD tissues. Conclusions: These findings reinforced the oncogenic role of METTL3 in LUAD progression and revealed its underlying correlation with cancer cell ferroptosis; these findings also indicate that METTL3 is a promising novel target in LUAD diagnosis and therapy.

14 December 2018 in Respiratory Research
Verified
Journal Article
Open access
PDF file
HSHua Su
Hua Su
XXXiaoling Xu
Xiaoling Xu
CYChao Yan
Chao Yan
YSYangfeng Shi
Yangfeng Shi
YHYanjie Hu
Yanjie Hu
RZRuifeng Zhang
Ruifeng Zhang
Pulmonary arterial hypertension (PAH) is related to inflammation, and the lncRNA H19 is associated with inflammation. However, whether PDGF-BB-H19-let-7b-AT1R axis contributes to the pathogenesis of PAH has not been thoroughly elucidated to date. This study investigated the role of H19 in PAH and its related mechanism. In the present study, SD rats, C57/BL6 mice and H19−/− mice were injected with monocrotaline (MCT) to establish a PAH model. H19 was detected in the cytokine-stimulated pulmonary arterial smooth muscle cells (PASMCs), serum and lungs of rats/mice. H19 overexpression and knockdown experiments were also conducted. A dual luciferase reporter assay was used to explore whether let-7b is a sponge miRNA of H19, and AT1R is a novel target of let-7b. A CCK-8 assay and flow cytometry were used to analyse cell proliferation. The results showed that H19 was highly expressed in the serum and lungs of MCT-induced rats/mice, and H19 was upregulated by PDGF-BB in vitro. H19 upregulated AT1R expression via sponging miRNA let-7b following PDGF-BB stimulation. AT1R is a novel target of let-7b. Moreover, the overexpression of H19 and AT1R could facilitate PASMCs proliferation in vitro. H19 knockout protected mice from pulmonary artery remodeling and PAH following MCT treatment. Our study showed that H19 is highly expressed in MCT-induced rodent lungs and upregulated by PDGF-BB. The H19-let-7b-AT1R axis contributed to the pathogenesis of PAH by stimulating PASMCs proliferation. The H19 knockout had a protective role in the development of PAH. H19 may be a potential tar-get for the treatment of PAH.

12 August 2015 in Journal of Ultrasound in Medicine
Verified
Journal Article
Open access
PDF file
WYWu Ye
Wu Ye
RZRuifeng Zhang
Ruifeng Zhang
XXXiaoling Xu
Xiaoling Xu
YLYanru Liu
Yanru Liu
KYKejing Ying
Kejing Ying
Objectives: Endobronchial ultrasound‐guided transbronchial needle aspiration (EBUS‐TBNA) is a minimally invasive technique. A meta‐analysis was performed to assess the efficacy and safety of EBUS‐TBNA in intrathoracic tuberculosis (TB).Methods: We searched PubMed, the Cochrane Library, and the Web of Science for suitable studies. The pooled sensitivity, specificity, likelihood ratios (LRs), and diagnostic odds ratio were calculated. A summary receiver operating characteristic (ROC) curve was constructed to calculate the area under the summary ROC curve and Qpoint value (Q*).Results: A total of 8 studies with 809 patients were included. The pooled sensitivity and specificity of EBUS‐TBNA for diagnosis of intrathoracic TB were 0.80 (95% confidence interval [CI] 0.74–0.85) and 1.00 (95% CI, 0.99–1.00), respectively. The positive LR was 38.25 (95% CI, 13.59–107.65); the negative LR was 0.24 (95% CI, 0.17–0.33); and the diagnostic odds ratio was 186.35 (95% CI, 63.57–546.28). The area under the summary ROC curve was 0.935, and the Q*was 0.871. The pooled sensitivity of EBUS‐TBNA for diagnosis of intrathoracic tuberculous lymphadenopathy was 0.87 (95% CI, 0.80–0.95). Only 1 serious complication was reported.Conclusions: Endobronchial US‐guided TBNA is an effective and safe diagnostic tool for intrathoracic TB, especially intrathoracic tuberculous lymphadenopathy.

7 July 2011 in Pharmacopsychiatry
Verified
Journal Article
Closed access
PDF file
RZR. Zhang
R. Zhang
LDL. Dong
L. Dong
FSF. Shao
F. Shao
XTX. Tan
X. Tan
KYKejing Ying
Kejing Ying
Antipsychotics have been inconclusively implicated in susceptibility to venous thromboembolism (VTE). The aim of this study was to investigate the association between antipsychotic drugs and VTE risk by a meta-analysis. PubMed and EmBASE databases were searched for publications through to 10 October 2010. Statistical analysis was performed using Revman 4.2 and Stata 10.0 software. 7 case-control studies involving 31 095 cases and 143 472 controls were analyzed. The results indicate that antipsychotic exposure confers a 139% increased risk of VTE (odds ratio [OR]=2.39, 95% confidence interval [CI]:1.71–3.35). Pooled estimates by drug type showed that use of low-potency antipsychotics (OR=2.91, 95% CI 1.80–4.71) is the most important risk factor for VTE, followed by atypical (OR=2.20, 95% CI 1.22–3.96), conventional (OR=1.72, 95% CI 1.31–2.24) and high-potency drugs (OR=1.58, 95% CI 1.50–1.67). This meta-analysis suggests that antipsychotics are a risk factor for VTE. Additional studies in large cohorts are required to validate our findings. Future analyses should study potential effect modifications by different doses and durations of antipsychotic exposure in different populations.

1 June 2016 in Journal of Breath Research
Verified
Journal Article
Open access
PDF file
JGJianping Gao
Jianping Gao
YZYingchang Zou
Yingchang Zou
YWYonggang Wang
Yonggang Wang
FWFeng Wang
Feng Wang
LLLang Lang
Lang Lang
KYKejing Ying
Kejing Ying
A number of multiresistant pathogens including Acinetobacter baumannii (A. baumannii) place a heavy burden on ventilator-associated pneumonia (VAP) patients in intensive care units (ICU). It is critically important to differentiate between bacterial infection and colonization to avoid prescribing unnecessary antibiotics. Quantitative culture of lower respiratory tract (LRT) specimens, however, requires invasive procedures. Nowadays, volatile organic compounds (VOCs) have been studied in vitro and in vivo to identify pathogen-derived biomarkers. Therefore, an exploratory pilot study was conceived for a proof of concept that the appearance and level of A. baumannii-derived metabolites might be correlated with the presence of the pathogen and its ecological niche (i.e. the infection and colonization states) in ICU ventilated patients. Twenty patients with A. baumannii VAP (infection group), 20 ventilated patients with LRT A. baumannii colonization (colonization group) and 20 ventilated patients with neurological disorders, but without pneumonia or A. baumannii colonization (control group) were enrolled in the in vivo pilot study. A clinical isolate of A. baumannii strains was used for the in vitro culture experiment. The adsorptive preconcentration (solid-phase microextraction fiber and Tenax(®) TA) and analysis technique of gas chromatography-mass spectrometry were applied in the studies. Breath profiles could be visually differentiated between A. baumannii cultivation in vitro and culture medium, and among in vivo groups. In the in vitro experiment, nine compounds of interest (2,5-dimethyl-pyrazine, 1-undecene, isopentyl 3-methylbutanoate, decanal, 1,3-naphthalenediol, longifolene, tetradecane, iminodibenzyl and 3-methyl-indene) in the headspace were found to be possible A. baumannii derivations. While there were eight target VOCs (1-undecene, nonanal, decanal, 2,6,10-trimethyl-dodecane, 5-methyl-5-propyl-nonane, longifolene, tetradecane and 2-butyl-1-octanol) exhibiting characteristics of A. baumannii VAP derivations. The selected VOC profile in vivo could be adopted to efficiently differentiate the presence of LRT A. baumannii from its absence, and LRT A. baumannii infection from its colonization (AUC = 0.89 and 0.88, respectively). It is not feasible to simply transfer the metabolic biomarkers from the in vitro condition to in vivo. The direct detection of exhaled A. baumannii-derived VOCs may be adopted for an early alert of the LRT bacterial presence in ventilated ICU patients, and even in different parasitic states of A. baumannii (i.e. infection and colonization). However, further refinement and validation are required before its clinical use.

25 July 2023 in Chest
Verified
Journal Article
Open access
DHDi He
Di He
MYMengsha Yan
Mengsha Yan
YZYong Zhou
Yong Zhou
HGHuiqing Ge
Huiqing Ge
XZXuhui Zhang
Xuhui Zhang
YZYimin Zhu
Yimin Zhu
Chronic obstructive pulmonary disease (COPD) was found to associate with frailty. However, there is inadequate longitudinal evidence for associations of COPD with frailty progression. Furthermore, recent studies revealed a new phenotype of lung function impairment: preserved ratio impaired spirometry (PRISm). Associations of PRISm and its transitions with frailty progression are unclear. What are the associations of PRISm, transitions of PRISm, and COPD with frailty progression? To analyze the associations of PRISm and COPD with frailty progression, 5,901 subjects were included from the English Longitudinal Study of Ageing. Subjects were classified into three lung function patterns of normal spirometry, PRISm, and COPD. Frailty progression was assessed by repeated measurements of the frailty index (FI) during follow-up. Among these 5,901 subjects, 3,765 subjects were included to analyze the associations of PRISm transitions with frailty progression. PRISm transitions were assessed based on the changes of lung function patterns after a four-year interval. Linear mixed-effect models were used for statistical analyses. The median follow-up periods were 9.5 years for the analyses of PRISm and COPD with frailty progression and 5.8 years for PRISm transitions with frailty progression. When compared with normal spirometry, subjects with PRISm and COPD presented accelerated FI progression with additional annual increases of 0.301(95%CI: 0.211 to 0.392, P<0.001) and 0.172(95%CI: 0.102 to 0.242, P<0.001), respectively. Subjects who transitioned from normal spirometry to PRISm also presented accelerated FI progression when compared with stable normal spirometry (β=0.242, 95%CI: 0.008 to 0.476, P=0.042). However, no accelerated FI progression was found in PRISm subjects who transitioned to normal spirometry (β=0.119, 95%CI: -0.181 to 0.418, P=0.438). Our findings indicate that PRISm and COPD are associated with accelerated frailty progression. Further studies are needed to elucidate the causality of PRISm and COPD with frailty.